Cardiol Therapeutics (CRDL)

$0.91 -0.01 (-1.09%)
Market Cap 76.63M
Revenue (ttm) 0.00
Net Income (ttm) -20.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 205,800
Avg Vol 254,204
Day's Range N/A - N/A
Shares Out 82.61M
Stochastic %K 14%
Beta 1.00
Analysts Strong Sell
Price Target $9.00

Latest News on CRDL

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Apr 1, 2025, 7:27 AM EDT - 2 days ago

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Mar 3, 2025, 7:27 AM EST - 4 weeks ago

Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Feb 20, 2025, 7:27 AM EST - 6 weeks ago

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts

Feb 19, 2025, 12:13 AM EST - 6 weeks ago

Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:27 AM EST - 2 months ago

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

Dec 19, 2024, 8:30 AM EST - 3 months ago

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Nov 18, 2024, 11:37 AM EST - 4 months ago

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Nov 13, 2024, 8:00 AM EST - 5 months ago

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

Oct 22, 2024, 6:30 AM EDT - 5 months ago

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option

Oct 11, 2024, 8:39 AM EDT - 6 months ago

Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

Oct 10, 2024, 9:09 AM EDT - 6 months ago

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

Oct 9, 2024, 7:58 AM EDT - 6 months ago

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Oct 8, 2024, 4:01 PM EDT - 6 months ago

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

Sep 24, 2024, 7:27 AM EDT - 6 months ago

Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Sep 10, 2024, 7:27 AM EDT - 7 months ago

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

Jun 27, 2024, 12:29 PM EDT - 10 months ago

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT

Jun 25, 2024, 7:27 AM EDT - 10 months ago

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Jun 13, 2024, 7:58 AM EDT - 10 months ago

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

May 14, 2024, 7:27 AM EDT - 11 months ago

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Apr 2, 2024, 6:00 AM EDT - 1 year ago

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Feb 21, 2024, 7:27 AM EST - 1 year ago

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Feb 15, 2024, 7:27 AM EST - 1 year ago

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market

Jan 24, 2024, 7:27 AM EST - 1 year ago

Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Jan 9, 2024, 7:27 AM EST - 1 year ago

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

Dec 5, 2023, 7:27 AM EST - 1 year ago

Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Nov 16, 2023, 5:30 AM EST - 1 year ago

Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis

Nov 1, 2023, 7:27 AM EDT - 1 year ago

Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Oct 20, 2023, 5:00 PM EDT - 1 year ago

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction

Oct 10, 2023, 6:00 AM EDT - 1 year ago

Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction

Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference

Sep 26, 2023, 7:27 AM EDT - 1 year ago

Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference

Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis

Sep 19, 2023, 7:27 AM EDT - 1 year ago

Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis

Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference

Aug 9, 2023, 7:27 AM EDT - 1 year ago

Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference

Cardiol Therapeutics Reports Results of 2023 Annual General Meeting

Jun 29, 2023, 10:19 AM EDT - 1 year ago

Cardiol Therapeutics Reports Results of 2023 Annual General Meeting

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDT

Jun 27, 2023, 7:27 AM EDT - 1 year ago

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDT

Cardiol Therapeutics Announces Year-End 2022 Update on Operations

Mar 29, 2023, 7:27 AM EDT - 2 years ago

Cardiol Therapeutics Announces Year-End 2022 Update on Operations

Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure

Mar 7, 2023, 7:27 AM EST - 2 years ago

Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure

Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx(TM) for the Treatment of Recurrent Pericarditis

Jan 17, 2023, 7:27 AM EST - 2 years ago

Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx(TM) for the Treatment of Recurrent Pericarditis

Cardiol Therapeutics Commences Multi-Center Phase II Pilot Study of CardiolRx(TM) for the Treatment of Recurrent Pericarditis

Dec 12, 2022, 7:27 AM EST - 2 years ago

Cardiol Therapeutics Commences Multi-Center Phase II Pilot Study of CardiolRx(TM) for the Treatment of Recurrent Pericarditis

Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases

Oct 25, 2022, 6:30 AM EDT - 2 years ago

Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx(TM) Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis

Oct 3, 2022, 7:27 AM EDT - 2 years ago

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx(TM) Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis

Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America

Sep 28, 2022, 8:20 AM EDT - 2 years ago

Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America

Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute Myocarditis

Aug 3, 2022, 7:29 AM EDT - 2 years ago

Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute Myocarditis

Cardiol Therapeutics Reports Results of 2022 Annual General Meeting

Jun 29, 2022, 10:07 AM EDT - 3 years ago

Cardiol Therapeutics Reports Results of 2022 Annual General Meeting

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT

Jun 27, 2022, 10:07 AM EDT - 3 years ago

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT

Cardiol Therapeutics Announces At-The-Market Equity Offering Program

Jun 9, 2022, 4:05 PM EDT - 3 years ago

Cardiol Therapeutics Announces At-The-Market Equity Offering Program

Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors

May 19, 2022, 7:27 AM EDT - 3 years ago

Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors

Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-Label Pilot Study of CardiolRx(TM) for Recurrent Pericarditis

May 17, 2022, 7:27 AM EDT - 3 years ago

Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-Label Pilot Study of CardiolRx(TM) for Recurrent Pericarditis

Cardiol Therapeutics Announces Year-End 2021 Update on Operations

Mar 24, 2022, 7:27 AM EDT - 3 years ago

Cardiol Therapeutics Announces Year-End 2021 Update on Operations

Cardiol Therapeutics to Participate in Cantor Fitzgerald's Virtual Rare Orphan Disease Summit

Mar 22, 2022, 7:27 AM EDT - 3 years ago

Cardiol Therapeutics to Participate in Cantor Fitzgerald's Virtual Rare Orphan Disease Summit

Cardiol Therapeutics Appoints Jennifer M. Chao to Its Board of Directors

Mar 15, 2022, 7:27 AM EDT - 3 years ago

Cardiol Therapeutics Appoints Jennifer M. Chao to Its Board of Directors